Welcome to Pharma and Biotech Patent Litigation 2025
This is Europe’s premier event for life sciences IP professionals. This January, join over 450 industry experts as we dive deep into the most pressing challenges and innovations in contentious IP law. Across three days of focused discussions and networking, you’ll gain valuable insights into the latest case law, regulatory updates, and strategic litigation approaches, while connecting with key stakeholders who drive the future of life sciences IP.
New for 2025
This year's summit will proudly host the industry's inaugural Women in IP workshop during our UPC Litigation Forum, featuring targeted workshop discussions. Additionally, we are introducing specialized and intimate litigation sessions tailored for the MedTech, large molecule, and small molecule sectors.
Why Should You Attend?
Elevate your patent litigation strategy by gaining insights into pressing legal challenges facing the life sciences sector. At this premier event, you'll dissect the first UPC decision on the merits, delve into the intricacies of SPCs and patentability issues, and explore the latest developments in cross-border case law and competition law.
Join Europe’s leading life science IP litigation professionals at the Beurs Van Berlage this January, where you'll engage in a cross-industry UPC Litigation Forum on January 20th, followed by a comprehensive summit focused on pharma and biotech patent litigation on January 21-22nd. This event offers a unique opportunity to forge essential commercial relationships with top stakeholders in the field, ensuring you're equipped to navigate the evolving landscape of life science IP litigation.
Highlights For 2025
Stay ahead of the curve with insights into the latest life science litigation, including cross-border cases, biosimilars, vaccines, and SPCs.
Gain actionable knowledge on the UPC’s impact on the life sciences sector, featuring industry-focused panels and a pre-event forum for practical, cross-industry discussions.
Engage in targeted, in-depth discussions with tracked sessions on MedTech, Large Molecule, and Small Molecule patent litigation.
Explore key updates and challenges in divisional patenting, PIs, second medical use, G2/21, and the Bolar exemption from top pharma and biotech IP specialists.
Gain unique insights into judicial perspectives through our global judges panel and the pre-event UPC Litigation Forum.
A Snippet Of Our In-House Speaker Faculty
Here Is What Your Peers Envision For The 2025 Edition Of This Event
Loading videos...
LIFE SCIENCES PATENT ADVISORY BOARD
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Patent Counsel
Roche
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel- Oncology Litigation
Novartis
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Associate General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Patent Counsel
Roche
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Senior Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel- Oncology Litigation
Novartis
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Adrian Spillmann
Director of Intellectual Property
Valneva
Julia Pike
Global Head of IP
Sandoz
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Head of IP
Sotio
Philip Caramanica
Chief IP Counsel & Deputy General Counsel
Alvotech
Register Your Interest for 2025
This conference offers numerous benefits for professionals in the Tech IP sector.
Explore In-House Insights: Discover the valuable perspectives from leading companies across telecoms, consumer tech, NPEs, Med Tech and automotive/mobility.
Engage in Targeted Sessions: Dive into the most pressing Tech patent litigation topics, including the UPC, interim licenses, SEP and FRAND enforcement topics, Trade Secrets and AI.
- Network with Top Firms: Gain insights from a diverse range of international and boutique patent litigation firms, participating as panellists and speakers, to enhance your understanding of the global litigation landscape.
- Hear from Key Decision-Makers: Learn directly from judicial and institutional speakers providing firsthand updates from critical bodies such as the UPC, UK courts, WIPO and the European Commission
See Below
A Snippet Of Our Private Practice Speaker Faculty
Paul Inman
PartnerGowling WLG
Eleanor Root
PartnerBird & Bird
Rob Cerwinski
PartnerGemini Law
Luca Pellicciari
PartnerTrevisan & Cuonzo
Daan De Lange
PartnerBrinkhof
Cecile Goy
PartnerAramis Law
Naomi Pearce
CEO and LawyerPearce IP
Agathe Michel-De-Cazotte
PartnerCarpmaels & Ransford
Tjibbe Douma
PartnerBird & Bird
Peter van Schijndel
PartnerHoyng Rokh Monegier
Benjamin May
PartnerAramis
Otto Swens
PartnerVondst
Oya Yalvac
PartnerDERIS
Denis Schertenleib
PartnerSchertenleib Avocats
Our 2024 Speakers
Agathe Michel-De-Cazotte
Partner
Carpmaels & Ransford
Andras Kupecz
Honourable Judge
UPC Munich Central Division
Andrew Hutchinson
Partner
Simmons & Simmons
Beat Weibel
Chief IP Counsel
Siemens
Beatriz Diaz de Escauriaza
Head of IP Legal
Insud Pharma
Carsten Richter
Head of IP
Euroimmun
Cecile Teles
Head of IP
Zentiva
Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.
Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.
Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.
Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.
Christoph Rehfuess
Head of IP
Sotio
Christopher Sharp
Partner
Pinsent Masons
Clemens Heusch
Head of Global Disputes and Resolution
Nokia
Conrad Eckhardt
Vice President IP
Biotronik
Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.
Edgar Brinkman
Honourable Judge
Court of the Hague (& UPC judge)
Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).
Eleanor Root
Partner
Bird & Bird
Emily Bottle
Partner
HSF Kramer
Filip De Corte
Head of IP
Syngenta
Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management. Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.
Filipe Pedro
Director of IP
BIAL
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Gabriele Mohsler
VP Patent Development
Ericsson
Gianluca Vassallo
Case Handler, DG Competition
European Commission
Guido Pontremoli
Vice President Global IP
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Heike Wollgast
WIPO
Ina Bürck
Senior Counsel
Amgen
James Horgan
Assistant General Counsel
MSD
Jiri Slavik
Vice President- Intellectual Property
Adalvo
Juliane Buchinski
Lead IP Litigation Counsel
ZTE
Karin Pramberger
Head of IP
Polpharma Group
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.
Katie Coltart
Partner
Linklaters
Laila Beynon
Director – Dispute Resolution
Regeneron
Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT.
Margot Kokke
Honourable Judge
UPC Court of First Instance
Mathias Zigann, Honourable Judge, UPC- Munich
Honourable Judge
UPC- Munich
Matthew O’Neill
Director of European IP
Glenmark Pharmaceuticals
Michael Swita
Director of Intellectual Property Policy
EFPIA
Mirna Atallah
Senior Director IP
Astellas Europe
Natalia Wright
Assistant General Patent Counsel
UCB
Philippe Bessiere
Global Head of Patents
Pierre Fabre Group
Raquel Frisardi
Senior Corporate Counsel
Novo Nordisk
Rob Rodrigues
Partner
RNA law
Ronny Thomas
Honourable Judge
UPC Local Division
Sara Burghart
Senior Counsel- Patent Litigation
BAT
Sean Alexander
Head of IP Strategy
Umicore
Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.
Sergio Napolitano
General Counsel
Medicines for Europe
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Stefan Luginbuehl
Head of Department European Legal Affairs
European Patent Office (EPO)
Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.
He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.
Stefanie Kies
Senior Director Intellectual Property
Polpharma Biologics
Sufiyah Sulaiman
Senior Patent Manager Patent Litigation
STADA
Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris).
Tess Waldron
Partner
Powell Gilbert
Tjibbe Douma
Partner
Bird & Bird
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Andre Andrade
Vice President, Client Relations EMEA and Law Firms,
RWS
Arvid van Oorschot
Partner
Vondst
Arvid is an IP-lawyer with over 20 years’ experience and partner of Vondst advocaten.
His main area of expertise is patent litigation. He works in various technical fields including MedTech, pharma and mechanical engineering. He works for instance on cases on antibodies and medical devices. He has a special interest in AI and legal tech.
He publishes and lectures regularly on the (international-) enforcement of IP rights and related issues.
Arvid is listed in various authoritative editorials including Chambers Europe and Global, Juve and IAM Patent 1000.
He is an active member of various professional associations including EPLAW and AIPPI.
Arvid studied at the Free University of Amsterdam and Northwestern Law School in Chicago. He was admitted to the bar in 2004.
Aude Veinante
European Patent Attorney
Lavoix
Aude assists her clients in defining their patent strategy. Aude drafts new patent applications and monitors grant procedures in France and abroad. Her work also includes conducting patentability, validity and freedom to operate studies as well as forming consultations relative to supplementary protection certificates (SPCs).
Aude performs audits in the pharmaceutical and life science fields and advises her clients in case of patent disputes.
Aude is a member of the AIPPI (International Association for the Protection of Intellectual Property) and the GRAPI (Groupe Rhône-Alpes pour la protection de la Propriété Intellectuelle [Rhône-Alpes Group for the Protection of Intellectual Property]). She is also a lecturer at the Bordeaux National School of Biomolecule Technology.
Bolko Ehlgen
Partner
Linklaters
Camille Pecnard
Partner
Lavoix
Catherine Drew
Partner
Pinsent Masons
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Daan De Lange
Partner
Brinkhof
Denis Schertenleib
Partner
Schertenleib Avocats
Douglas McCann
Principal
Fish & Richardson
Enzo Marasa
Partner
Portolano Cavallo
Ewan Nettleton
Principal IP Counsel- Oncology Litigation
Novartis
Gaëlle Bourout
Counsel
Linklaters
Gemma Barrett
Partner
A & O Shearman
Gemma is an experienced and trusted advisor for some of the world’s leading life sciences and chemical companies. Her background in biochemistry means she specialises in complex technical disputes in the life sciences sector. She has more than fifteen years’ experience advising clients in patent litigation matters before the English Courts including securing preliminary injunctions. She is also experienced in advising on global cross-border litigation, and coordinating worldwide litigation, working closely with multi-disciplinary teams in the defence and enforcement of patent portfolios. She has developed innovative and successful strategies, often combining patent and regulatory law, to assist pharmaceutical companies in the enforcement of their rights.
Georgia Roussou
Senior Legal Counsel
Win Media
Heike Röder-Hitschke
Counsel
Maiwald
Jason Raeburn
Partner
Paul Hastings
Jenny Davies
Partner
Gowling
Jenny Davies is a life sciences and patent specialist with a Masters in Biochemistry from Oxford. She provides strategic advice to help clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. Her work regularly entails negotiating agreements to support her clients' research, development, manufacture and commercialisation, and protect their markets through the enforcement of patents.
Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. She advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.
Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".
Her work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).
Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.
John Cox
Partner
Barnes & Thornburg
With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.
Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.
John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.
John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.
Kassie Helm
Partner
Dechert
Lauren Baker
Associate
Barnes & Thornburg
Manuel Neetz
IP Counsel
Siemens Healthineers
Marc Lauzeral
Partner
Schertenleib Avocats
Marco Stief
Partner
Maiwald
Marie Hovel Hansen
Head of Legal Strategy & Operations, Trademarks and Global Litigations
Novonesis
Martina Tyreus Hufnal
Principal
Fish & Richardson
Mike Cottler
Partner
Gemini
Özge Atılgan Karakulak
Partner
Gün + Partners
Paul Ainsworth
Director
Sterne Kessler
Pierre-Emmanuel Meynard
Partner
Lavoix
Rainer Friedrich
Director of Global IP and Biotech Technical Judge
CSL Behring and the UPC
Robert Cerwinski
Managing Partner
Gemini Law
Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing. Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China. Mr. Cerwinski was named an IAM Global Leader in Intellectual Property Law in 2021 and is ranked in the Gold Tier of the IAM Patent 1000.
Robin Ellis
Partner
Reddie&Grose
Robin is a partner at Reddie & Grose, a full-service IP firm with offices in London, Munich and Cambridge.
Robin's practice focuses on multi-jurisdictional European litigation in the life science space. He regularly represents clients in opposition and appeal proceedings before the European Patent Office and has more recently advised clients on the fledgling SPC manufacturing waiver regulation.
Robin's 25 years in the profession has been split between roles in-house and private practice, which has given him a unique perspective on how to manage the multitude of IP issues now facing a pan-European product launch, including the introduction of the unified patent court.
Siddharth Kusumakar
Partner
Powell Gilbert
Testimonials From 2024 Attendees
The Pharma/Biotech Patent Litigation Europe Conference was very informative and offered many opportunities for networking with relevant contacts.
Victoria Flowers, Executive Director Forensics, Mazars
Brilliantly organised event, great mix of practice and industry attendees, a highly relevant and useful series of panel talks, and a good balance of networking and content.
Michael Lee, Senior Director of Patents, Norgine
Two inspiring days! Once again attending this conference proved to be to be a unique opportunity not only to see colleagues and friends from all over the world and for new connections, but also to catch up and discuss with them the latest developments in current topics in pharma and biotech patent litigation.
Maria Balestriero, IP Lawyer, Portolano Cavallo
Interesting presentations and many good discussions that are both informative and thought provoking
Adrian Spillman, Director IP, Valneva Group
Great and actual topics, presentations from all kinds of different angles, open discussions, new insights. All in all very well organised!
Dominique van De Kamp, Vice President of Intellectual Property Litigation and European Patent Attorney, Synthon
Great event delivering valuable insight from all aspects of the pharma sector! Definitely the go to IP litigation conference this year!
Delicia Clarke, Legal Consultant, Regeneron Pharmaceuticals
Very stimulating event, relevant topics, good panels, lively discussions.
Beatrix Otte, Head of IP, Tillotts Pharmaceuticals
The event this year was well attended and thought provoking.
Jennifer Sunderland, Senior Patent Litigation Counsel, Mylan
Our 2025 Partners
Interested in how you can get involved with Pharma & Biotech Patent Litigation 2025?
Based on your objectives, we can create bespoke packages for you. From presenting your expertise on stage to partnering with us to deliver networking activities. Partner with us in 2025 to showcase your brand and make valuable new connections. Opportunities include thought leadership, branding, and networking.
Discuss your objectives with Duncan Henderson, Commercial Partnerships Director, [email protected]
Tech & Innovation Patent Advisory Board
Milan Patel
IP Director- Patent Portfolio Management & Strategy - Patent Litigation
Volvo
Le Chen
Senior Director- IP Policy & Dispute Resolution
Xiaomi Technology
Gabriele Mohsler
VP Patent Development
Ericsson
Julia Dias
Senior IP Policy Counsel
Huawei
Clemens Heusch
Head of Global Disputes and Resolution
Nokia
Georg Müller
Head of IP
Tom Tom
Dr. Georg Müller is Swiss and European Patent Attorney and leads TomTom’s IP team as Head of IP. Prior to this, he oversaw Strategic IP Counsel the IP activities of the Grid Automation Business Unit of Hitachi Energy. Dr. Müller started his professional career in Research and Development at ABB Corporate Research. He holds a doctoral degree in physics after studies of physics in Göttingen, Hannover, and Santa Barbara.
Milan Patel
IP Director- Patent Portfolio Management & Strategy - Patent Litigation
Volvo
Le Chen
Senior Director- IP Policy & Dispute Resolution
Xiaomi Technology
Gabriele Mohsler
VP Patent Development
Ericsson
Julia Dias
Senior IP Policy Counsel
Huawei
Clemens Heusch
Head of Global Disputes and Resolution
Nokia
Georg Müller
Head of IP
Tom Tom
Dr. Georg Müller is Swiss and European Patent Attorney and leads TomTom’s IP team as Head of IP. Prior to this, he oversaw Strategic IP Counsel the IP activities of the Grid Automation Business Unit of Hitachi Energy. Dr. Müller started his professional career in Research and Development at ABB Corporate Research. He holds a doctoral degree in physics after studies of physics in Göttingen, Hannover, and Santa Barbara.
IN PARTNERSHIP WITH
Diamond Partner
A&O Shearman
Website: www.aoshearman.com/en
A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets. This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world.
Our trade secrets group operates on a multi-jurisdictional, cross-disciplinary basis, involving lawyers from our intellectual property and employment teams, as well as our litigation, investigations, white-collar crime, and arbitration specialists. We provide services to innovative clients across a range of sectors, including financial services, life sciences, defence, aerospace, chemicals, telecoms and high technology.
Fisher & Richardson
Website: www.fr.com
Fish helps pioneering life sciences and AI companies to optimize the process of creating new drugs through AI-assisted drug development and discovery. As one of the most experienced AI law firms, Fish aids clients in navigating patent strategy and protection, including application of the "simultaneous conception and reduction to practice doctrine," licensing and collaboration agreements, trade secret protection, regulatory and compliance, litigation and enforcement, and strategic AI planning. Our ability to pair dynamic legal strategies with in-depth Life Sciences industry experience is what separates Fish from other law firms. At Fish, we’ve prosecuted the patents for some of the essential technologies that underpin today’s cutting-edge AI services. AI innovation is advancing faster than the law can catch up, and it takes knowledgeable legal teams to stay on pace. With technical prowess virtually unheard of in the legal industry, Fish’s attorneys have been working with revolutionary technologies for decades. As a result, we know better than most how to protect our clients’ assets when they push the boundaries of IP law.
Platinum Partners
Bonabry
Website: www.bonabry.de
Bonabry is a team of experienced and specialized patent and IP litigators united in the belief that the most excellent solutions for our clients require independent and inventive thinking supported by a working environment that implements the ideas of tomorrow. The team is composed of five partners (Dr Alexander Harguth, Carl-Alexander Dinges, Daniel Hoppe, Dr Jan Peter Heidenreich and Konstantin Schallmoser), two counsels (Christian Holtz and Dr Sarah Salaschek) and two associates (Alice Pasch and Isabel Werner). The new offices are based in Hamburg, Munich, and Paris.
Bonabry represents its clients in all areas of IP litigation and licensing. Their services include patents, trade secrets, trademarks, copyrights, designs, and related fields such as competition law and pharma regulatory law. The key industries include life science and pharma, telecommunication and network technology, automotive, industrial engineering, semiconductors, electronics and software, cosmetic and consumer goods as well as luxury goods and fashion.
Clifford Chance
Website: www.cliffordchance.com/home.html
Clifford Chance is one of the world’s pre-eminent law firms, with significant depth and range of human and IT resources across five continents. The firm is always striving to exceed the expectations of its clients, which includes banks and other financial institutions, corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not-for-profit organisations. Providing the highest quality advice and legal insight, Clifford Chance prides itself on its approachable, team-based and tech-savvy way of working.
DERIS
Website: www.deris.com
Deris is a one-stop shop for IP services with one of the largest and internationally regarded IP prosecution and advisory team.
We have been the pioneer in shaping the IP landscape by obtaining the precedent decisions & participating the preparation of the IP legislation upon the invitation of the legislative bodies. We provide a wide spectrum of high-quality services that are essential for securing, maintaining and enforcing IP rights.
Our services and counseling are supported by the trademark attorneys and technical experts, who are national and European patent attorneys, under a unique service approach combining longstanding enforcement experience with prosecution-technical expertise. Our goal is to secure enforceable IP rights in the market so that they can be transformed into sustainable commercial values.
Herbert Smith Freehills Kramer
Website: www.herbertsmithfreehills.com
Please visit our website for more information.Hoyng Rokh Monegier
Website: www.hoyngrokhmonegier.com
Please visit our website for more information.Linklaters
Website: www.linklaters.com
Linklaters cross-border Intellectual Property team successfully advises market-leading companies on high-profile IP litigation and complex IP-driven transactions.
We advise clients in a broad range of sectors, with a focus on IP-heavy industries such as healthcare and life sciences.
Our history of advising clients in the healthcare and life sciences sector is long and we have developed strong working relationships and a deep understanding of our client’s business environment. Many of our lawyers have technical backgrounds and therefore have in-depth understanding of complex technologies.
We support our clients with outstanding legal skills, expert sector knowledge and a pragmatic mindset in cross-border IP disputes. More specifically our litigation practice covers the full scope of dispute resolution, including court proceedings, arbitration, mediation and settlement discussions. Where possible, we aim to resolve disputes before court proceedings become necessary. However, where litigation is unavoidable, we take care to pick the right cases to pursue through the courts and continue to look for pragmatic solutions.
We tackle the entire spectrum of IP rights, including patents, supplementary protection certificates, copyrights, designs and trademarks. Our practice also covers issues of confidentiality, as well as trade secrets protection and misappropriation.
Marks & Clerk
Website: www.marks-clerk.com
Marks & Clerk is an international law firm specialising in intellectual property (IP) law. With a vast network of over 650 professionals across the world, including a qualified team of experienced patent and trademark associates, the firm offers comprehensive technical expertise covering all aspects of intellectual property matters, such as patents, trademarks, designs and copyright. Its services encompass worldwide protection, portfolio management, strategic advice, commercial guidance, licensing, enforcement, clearance and searches, validity and infringement opinions, due diligence and litigation. Operating through a network of offices in Canada, Europe and Asia, Marks & Clerk consistently delivers high-quality, seamless and cost-effective services to clients both locally and globally.
Potter Clarkson
Website: www.potterclarkson.com
Leading European intellectual property law firm, Potter Clarkson helps companies, organisations, and individuals across all sectors of business to understand, create, protect, and defend the commercial value of their innovations anywhere in the world. Its 200-strong specialist team of patent attorneys, trade mark attorneys, litigators, and licensing specialists, operate from dedicated offices in the UK, Sweden, and Denmark.
Potter Clarkson is widely recognised as one of Europe’s leading intellectual property law firms, particularly renowned for its expertise in life sciences disputes. The firm’s contentious practice regularly handles high-profile litigation across major jurisdictions worldwide, including proceedings before the European Patent Office (EPO) and, more recently, the Unified Patent Court (UPC). With multiple actions currently underway, Potter Clarkson is actively leveraging the EPO’s existing procedures to obtain Unitary Patents and enforce patent rights across Europe through the UPC.Potter Clarkson is widely recognised as one of Europe’s leading intellectual property law firms, particularly renowned for its expertise in life sciences disputes. The firm’s contentious practice regularly handles high-profile litigation across major jurisdictions worldwide, including proceedings before the European Patent Office (EPO) and, more recently, the Unified Patent Court (UPC). With multiple actions currently underway, Potter Clarkson is actively leveraging the EPO’s existing procedures to obtain Unitary Patents and enforce patent rights across Europe through the UPC.
Potter Clarkson is widely recognised as one of Europe’s leading intellectual property law firms, particularly renowned for its expertise in life sciences disputes. The firm’s contentious practice regularly handles high-profile litigation across major jurisdictions worldwide, including proceedings before the European Patent Office (EPO) and, more recently, the Unified Patent Court (UPC). With multiple actions currently underway, Potter Clarkson is actively leveraging the EPO’s existing procedures to obtain Unitary Patents and enforce patent rights across Europe through the UPC.
Schertenleib
Website: schertenleib-avocats.com/en/equipe/denis-schertenleib
Please visit our website for more information.Taylor Wessing LLP
Website: www.taylorwessing.com/en
Taylor Wessing is a global law firm that serves the world's most innovative people and businesses. Deeply embedded within the life sciences & healthcare, technology, media & communications (TMC), energy & infrastructure, private wealth and real estate sectors, we work closely together with our clients to crack complex problems, enabling ideas and aspirations to thrive. With a team of 1,200 lawyers working across 28 offices in 17 countries, we challenge expectation and create extraordinary results.
Our team work with some of the largest pharmaceutical, biotechnology, and medical device companies and healthcare providers in the world to a diverse collective of small-to-medium-sized start-up enterprises ready to upscale their business, and many companies in between.
Gold Partners
Carpmaels & Ransford
Website: www.carpmaels.com
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.
EIP
Website: www.eip.com/uk
EIP specialises in high-value and complex patent matters. Our multidisciplinary team combines patent attorneys, litigators and commercial IP lawyers, and we have specialists in three of the world’s main patent markets - Germany, UK and US, and now also in the Nordics through our recent expansion into Sweden.
The benefit of this combination is well illustrated by EIP’s successful representation of clients in high stakes patent litigation before the UK High Court, Court of Appeal and Supreme Court and before the German District and Federal Courts.
Our contentious expertise extends to conducting offensive and defensive oppositions before the European Patent Office, often involving multiple parties and relating to cutting edge platform technologies, to representing clients in national litigation proceedings in the UK and Germany, and since 1 June 2023, also the UPC.
Our litigation practice has built an enviable reputation for quality and success amongst its competitors and clients, with a strong track record including a landmark ruling on Standard Essential Patents (SEPs) from the UK Supreme Court. Our patent attorneys work hand-in-hand with the litigation team in the UK and Germany, to provide technical expertise and put forward the very best case on large scale international patent litigation matters.
In addition to our existing UK, German and Swedish capabilities, EIP Amar, an alliance between EIP and Amar Goussu Staub in Paris, is a dedicated, experienced and technically skilled team of patent litigation specialists created to support clients in any high-stakes litigation before the UPC.
EIP is increasingly involved in advisory and strategic project work in relation to the enforcement of patent rights, including portfolio analyses, infringement and validity analyses and claim charting, and strategic IP advice such as due diligence related to acquisitions and joint ventures.
EIP’s Life Sciences team offers multi-qualified and multi-disciplinary teams to suit the specific needs of each client. Innovations in this sector are increasingly intersectional and, by bringing together life sciences expertise with EIP’s long established strengths in areas such as artificial intelligence and machine learning, our team provides an inter-disciplinary life sciences offering that keeps pace with such innovations.
Finnegan
Website: www.finnegan.com
As one of the largest IP practices in the world, Finnegan was founded nearly 60 years ago with a focus on offering the highest quality IP legal services. Since we focus primarily on IP, every resource of our firm is dedicated to hiring the top talent in the IP world, and providing them with the IP resources needed to excel. We have a decades-long track record of successfully prosecuting and litigating some of the world’s most significant patent, trademark, copyright, and licensing matters. We also represent clients on IP issues related to advertising, trade secrets, European patents and trade marks, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, privacy, and unfair competition. We offer full-service IP legal and technical experience in virtually every industry and technology—from electrical and computer technology, industrial manufacturing, consumer products, medical devices, and biotechnology to pharmaceuticals, chemicals, and alternative energy.
Our commitment to quality is continually recognized worldwide by our clients, colleagues, and respected publications such as:
- #1 Tier National Ranking for Intellectual Property Law, 2010-2024 (U.S. News—Best Lawyers Best Law Firms)
- Practice Group of the Year, 2017, 2019, 2022 (Law360)
- #1 Tier National Ranking for Intellectual Property Litigation, 2024 (Benchmark Litigation)
LAVOIX
Website: www.lavoix.eu/en
LAVOIX, a European firm fully dedicated to Intellectual Property (IP), has close to 200 IP professionals including 80 attorneys-at-law, industrial property attorneys and technology specialists.The firm’s sheer size and the diversity of its team’s areas of expertise enable LAVOIX to assist its clients in every aspect of IP across all business areas and technological fields.
Our Life Science team has extensive technical expertise in many areas including biotechnology, pharmaceutical chemistry and bioinformatics.
Our attorneys are able to prosecute patent applications in the three European Patent Office official languages (English, German and French). Our Munich office provides direct and easy access to the EPO and the German Patent Office.
Our Life Science team is also regularly involved in oppositions, appeals and oral proceedings before the EPO, management of Supplementary Protection Certificates, as well as due diligence, precontentious opinions and national or pan-European litigations.
With a view to maximize the position of our clients and meet their specific needs, our Life Science Team also monitors the latest developments of the European Union’s law which could potentially affect our client’s businesses, in particular in respect of pharmaceuticals, chemicals, agrochemicals and medical devices.
Mewburn Ellis
Website: www.mewburn.com
Mewburn Ellis is one of leading P firms in Europe, showcasing an exceptional breadth and depth of expertise to address all your IP needs, both now and in the future. With five European offices – London, Bristol, Manchester, Cambridge, and Munich – we operate seamlessly as one unified firm. This ensures our clients benefit from a diverse range of relevant skills and knowledge, delivered by some of the brightest minds in the IP profession. Our IP specialists will guide you through every stage of the IP lifecycle. We offer comprehensive advice on patent, trade mark, and registered design protection, as well as assistance with any IP-related disputes and legal or commercial requirements. If you need help reviewing your IP assets, we can conduct IP Audits to evaluate your existing IP portfolio, identifying related risks and opportunities, and providing strategic advice and guidance aligned to your business objectives.
At Mewburn Ellis, we bring passion and commitment to our clients, immersing ourselves in their businesses to understand not just their immediate needs, but also their long-term goals. This strategic and personalised approach allows us to deliver creative and cost-effective solutions tailored to each client's specific requirements.
Michalski Huttermann & Partner
Website: mhpatent.de/en
Please visit our website for more information.Osborne Clarke
Website: www.osborneclarke.com/locations/germany
Please visit our website for more information.RPX
Website: www.rpxcorp.com
RPX Corporation is the leading patent risk management platform, offering defensive buying, acquisition syndication, patent intelligence, and advisory services. Since its founding in 2008, RPX has introduced efficiency to the patent market by providing a rational alternative to litigation. The San Francisco-based company’s pioneering approach combines principal capital, deep patent expertise, and client contributions to generate enhanced patent buying power. By acquiring patents and patent rights, RPX helps to mitigate and manage patent risk for its growing client network. As of July 1, 2025 RPX has invested nearly $5B to acquire rights to more than 300,000 US and international patent assets on behalf of more than 265 clients.
Solutions Partner
RWS
Website: www.rws.com/intellectual-property-services
RWS is a content solutions company, powered by technology and human expertise. We grow the value of ideas, data and content by making sure organizations are understood. Everywhere.
Our proprietary technology, 45+ AI patents and human experts help organizations bring ideas to market faster, build deeper relationships across borders and cultures, and enter new markets with confidence – growing their business and connecting them to a world of opportunities.
It’s why over 80 of the world’s top 100 brands trust RWS to drive innovation, inform decisions and shape brand experiences.
With 60+ global locations, across five continents, our teams work with businesses across almost all industries. Innovating since 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
More information: rws.com
TPR
Website: www.tprinternational.com
TPR is a world-class leader in patent and literature research for the pharmaceutical and biotechnology industries, trusted for over 30 years. Our team of specialised Search Analysts, known for their global reputation for excellence, provides actionable insights to support IP protection, innovation, and strategic decision-making.
Chemistry & Biotech Expertise – Advanced searches in both large and small molecules leveraging cutting-edge indexing and algorithms, including chemical structures, Markush structures, sequences, formulations and biosimilars.
Comprehensive Subject Knowledge – Our team includes experts in molecular biology, immunology, genomics, gene therapy, and medical devices, with many Search Analysts formerly serving on the patent information teams at leading companies such as GSK, Merck, Pfizer, Novartis, Abbott, Eli Lilly, Amgen and Genentech.
Tailored Patent Search Solutions – From freedom-to-operate to validity/invalidity, litigation, EPO opposition, IPR, due diligence, landscape and white-space analyses, we address the critical challenges in pharma and biotech.
TPR’s highly experienced U.S. and European Search Analysts, global reach, and passion for excellence make us the most trusted choice for pharma and biotech corporations and law firms.
Pi Pharma Intelligence
Website: pipharmaintelligence.com
Pi Pharma Intelligence is a leading provider of pharmaceutical patent and IP intelligence, supporting counsel, portfolio managers, and litigation teams in navigating complex global IP landscapes. Our platform, Pi Insight, integrates more than 265,000 granted patents and 400,000 applications, with detailed tracking of SPCs, exclusivities, regulatory extensions, and litigation-relevant milestones.
We deliver Freedom-to-Operate and Access Barrier Reports that assess enforceability, scope, and blocking rights across jurisdictions, while identifying potential white spaces and pathways for lawful market entry. Our Portfolio Risk Reports project expiry cliffs, competitive filings, and exclusivity erosion—enabling informed decision-making for infringement defense, licensing negotiations, and lifecycle management.
With particular strength in the MENA region, Pi Pharma standardizes local IP and regulatory data, providing timely alerts on status changes often overlooked by global databases.
By combining rigorous legal analytics with actionable intelligence, Pi Pharma equips IP professionals to anticipate disputes, mitigate exposure, and safeguard innovation.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.